Novacyt Stock price

Equities

ALNOV

FR0010397232

Biotechnology & Medical Research

Real-time Euronext Paris 10:03:30 2024-03-28 am EDT 5-day change 1st Jan Change
0.505 EUR -1.94% Intraday chart for Novacyt -0.79% -29.17%
Sales 2021 95.78M 103M Sales 2022 21.04M 22.68M Capitalization 76.79M 82.79M
Net income 2021 -9M -9.7M Net income 2022 -25M -26.95M EV / Sales 2021 1.67 x
Net cash position 2021 99.9M 108M Net cash position 2022 86.29M 93.04M EV / Sales 2022 -0.45 x
P/E ratio 2021
-26.3 x
P/E ratio 2022
-2.99 x
Employees 120
Yield 2021 *
-
Yield 2022
-
Free-Float 96.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.68%
1 week+1.87%
Current month+0.68%
1 month-2.17%
3 months-26.97%
6 months-23.75%
Current year-27.28%
More quotes
1 week
0.50
Extreme 0.501
0.53
1 month
0.49
Extreme 0.4932
0.55
Current year
0.49
Extreme 0.4932
0.72
1 year
0.42
Extreme 0.42
1.00
3 years
0.42
Extreme 0.42
8.49
5 years
0.06
Extreme 0.0612
13.96
10 years
0.06
Extreme 0.0612
13.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 21-01-04
Director of Finance/CFO 41 17-03-31
Chief Tech/Sci/R&D Officer - 16-04-30
Members of the board TitleAgeSince
Director/Board Member 76 15-06-28
Director/Board Member 69 23-09-07
Director/Board Member 51 23-09-07
More insiders
Date Price Change Volume
24-03-28 0.505 -1.94% 81 704
24-03-27 0.515 -0.29% 85,622
24-03-26 0.5165 -0.96% 71,015
24-03-25 0.5215 +0.10% 74,703
24-03-22 0.521 +2.36% 91,017

Real-time Euronext Paris, March 28, 2024 at 05:55 am EDT

More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Novacyt - Euronext Paris